Vnitr Lek 2020, 66(7):443-446 | DOI: 10.36290/vnl.2020.125

Tangier disease in family with the phenotype of familial hypercholesterolemia

Robin Urbánek1, Lukáš Tichý2, Tomáš Freiberger3
1 Lipidová a obezitologická ambulance, Zlín
2 Interní hematoonkologická klinika, Centrum molekulární biologie a genové terapie, FN Brno
3 Centrum kardiovaskulární a transplantační chirurgie. Genetická laboratoř, FN u sv. Anny Brno

Within the project MedPed (Make Early Diagnosis to Prevent Deaths) we have examined patient with familial hypercholesterolemia in our lipid ambulance. During the following investigation of the patient's family we found out that her sister has on the contrary very low levels of total and LDL-cholesterol. Concentration of HDL-cholesterol was extreamly low (almost immeasurable). Differential diagnosis uttered a suspicion of rare form of familial hypoalfalipoproteinemia so-called Tangier disease. This suspicion was then confirmed by molecular genetic examination. Tangier disease is a rare lipoprotein metabolism disorder characterized biochemically by almost complete absence of plasmatic HDL- cholesterol, extremely low level of apolipoprotein A-I and accumulation of cholesterol esters in macrophages. The first case was recorded on the Tangier island in 1961. In our research we describe the first case of a patient with homozygous form of Tangier disease in the history of the Czech Republic.

Keywords: familial hypercholesterolemia, low ApoA‑I, low HDL‑cholesterol, primary hypoalfalipoproteinemia, project MEDPED, Tangier disease.

Published: November 3, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbánek R, Tichý L, Freiberger T. Tangier disease in family with the phenotype of familial hypercholesterolemia. Vnitr Lek. 2020;66(7):443-446. doi: 10.36290/vnl.2020.125.
Download citation

References

  1. Fredrickson DS, Altrocchi PH, Avioli L, et al. Tangier Disease‑combined clinical staff conference at the National Institute of Health. Ann Intern Med 1961; 55: 1016. Go to original source...
  2. Puntoni M, Sbrana F, Bigazzi F, Sampietro T. Tangier disease: epidemiology, pathophysiology and management. Am J Cardiovasc Drugs 2012 (5): 303-313. Go to original source...
  3. Luchci T, Calandra S, Rabacchi C, Conti G, Ardolino G, Assolari L, Arosio B, Vergani C. A man with low cholesterol and weakness of the lower limbs: Intern Emerg. Med (2014) 9: 449-453. Go to original source... Go to PubMed...
  4. Tall AR, Breslow JL, Rubin EM. Genetic disorders affecting plasma high‑density lipoproteins. In: Scriver CR, Beaudot AL, Valle D, Sly WS (eds) The metabolic and molecular bases of inherited disease, 8th edition New York, Mc Graw‑Hill, 2001, pp 2915-2936.
  5. Santos RD, Asztalos BF, Martinez LR, et al. Clinical presentation, laboratory values, and coronary heart disease risk in marked high‑density lipoprotein‑deficiency states. J Clin Lipidol. 2008; 2: 237-247. Go to original source... Go to PubMed...
  6. Schaefer EJ, Santos RD, Asztalos BF. Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol. 2010; 21: 289-297. Go to original source... Go to PubMed...
  7. Schaefer EJ, Anthanont P, Diffenderfer MR, Polisecki E, Asztalos BF. Diagnosis and tretment of high density lipoprotein deficiency. Prog Cardiovasc, DiS. 2016 Sep‑Oct; 59(2): 97-106. Go to original source... Go to PubMed...
  8. Fasano T, Zanoni P, Rabacchi C, Pisciotta L, Favari E, Adorni MP, Deegan PB, Park A, Hlaing T, Feher MD, Jones B, Uzak AS, Kardas F, Dardis A, Sechi A, Bembi B, Minuz P, Bertolini S, Bernini F, Calandra S. Novel mutations of ABCA1 transporter in patients with Tangier disease and familial deficiency. Mol Genet Metab. 2012 Nov; 107(3): 534-541. Go to original source... Go to PubMed...
  9. Clee SM, Kastelein J, van Dam M, Marcil M, Roomp K, Zwarts KY, Collins JA, Ceska R, Stulc T,Roelants R, Tamasawa N, Frohlich J, Hayden MR, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes, J.Clin Invest 106 (2000) 1263-1270. Go to original source... Go to PubMed...
  10. Hooper AJ, McCormick SPA, Hegele RA, Burnett JR. Clinical utility gene card for: Tangier disease.Europeran Journal of Human Genetics (2017)25. Go to original source... Go to PubMed...
  11. Muratsu J, Koseki M, Masuda D,Yasuga Y, Tomoyama S, Keiji S,Ataka K, Yagi Y, Nakagawa A, Hamada H, Fujita S, Hattori H, Ohama T, Nishida M, Hiraoka H, Matsuzawa Y, Yamashita S Accelerated atherogenicity in Tangier disease. A case accompanied by extensive atherosclerotic lesions, Leriche syndrom and bleeding tendency, and Review of the literature. J Atheroscler Thromb 2018 Oct 1; 25(10): 1076-1085. Go to original source... Go to PubMed...
  12. Stocchi L, Giardina E, Varriale L, Sechi A, Vagnini A, Parri G, Valentini M, Capalbo M. Can Tangier disease cause male infertility? A case report and an overview on genetic causes of male infertility and hormonal axis involved. Molec.Gene. and Metab 123 (2018) 43-49. Go to original source... Go to PubMed...
  13. Brooks‑Wilson A, Marcil MClee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne‑Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frochlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR. Mutations in ABCA in Tangier disease and familial high‑density lipoprotein deficiency, Nat Genet 22 (1999) 336-345). Go to original source... Go to PubMed...
  14. Hobbs HH, Rader DJ. ABCA1: connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest.104 (1999) 1015-1017. Go to original source... Go to PubMed...
  15. Petrini V, Rizzuto N, Vergani C, et al (1985) Neuropthy in Tangier disease: a clinicopathologic study and a review of the literature. Acta Neurol Scand 72(5): 495-505. Go to original source... Go to PubMed...
  16. Rader DJ, deGoma EM. Aproach to the patient with extremely low HDL‑cholesterol, J Clin Endocrinol Metab, (2012),97 (10): 3399-3407. Go to original source... Go to PubMed...
  17. Negi SI, Brautbar A, Virani SS, Anand A, Polisecki E, Asztalos BF et al. A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease. J Clin Lipidol 7 (2012) 82-87. Go to original source... Go to PubMed...
  18. Oram JF, Vaughan AM. ATP‑Binding cassette cholesterol transporters and cardiovascular disease. Circ Res. 2006; 99(10): 1031-1043. Go to original source... Go to PubMed...
  19. Hegele RA, Borén J, Ginsberg HN, Arca M, Averna M, Binder CHJ, Calabresi L, Chapman MJ, Cuche Ml, Eckardstein A, Frikke‑Schmidt R, Gaudet D, Hovingh GK, Kronenberg F, Lütjohann D, Parhofer HG, Raal FJ, Ray KK, Remaley AT, Stock JK, S Stroes ES, Tokgözoğlu L, Catapano AL. Rare dyslipidemias, from phenotype to genotype to management: a European Atherosclerosis Society task force concensus statement. Lancet Diabetes Endocrinol 2019 S2213-8587(19)Další literatura u autoraa na www.casopisvnitrnilekarstvi.cz
  20. Singh V N, Editor: Griffing G T, et al. Low HDL Cholesterol (Hypoalphalipoproteinemia) Nov 03 (2016), https://emedicine.medscape.com/article/127943-clinical#b5
  21. Vrablik M, Vaclova M, Tichy L, et al. Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed project. Physiol Res. 2017: 66 (Suppl 1): S1-9. Go to original source... Go to PubMed...
  22. Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May; 17 (5): 405-424. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.